Tracer library / [64Cu]SarAr-PEG10-Tz
[64Cu]SarAr-PEG10-Tz
Also written as [Cu-64]Cu-SarAr-PEG10-Tz
- Radionuclide
- Cu-64 t½ 762 min
- Modality
- PET
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- Sarcophagine-tetrazine bifunctional chelator conjugate (SarAr-PEG10-Tz)
- Target / mechanism
- Tetrazine-trans-cyclooctene inverse electron-demand Diels-Alder (IEDDA) pretargeting ligation with TCO-bearing huA33 anti-A33 antibody PMID 41605863
- Clinical application
- Pretargeted immunoPET imaging in a murine model of colorectal cancer PMID 41605863
- Theranostic pair
- [67Cu]Cu-SarAr-PEG10-Tz
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | >99% | >99% | SarAr-PEG10-Tz | 41605863 2026 Mol Pharm SarAr-Tz, SarAr-PEG5-Tz, and SarAr-PEG10-Tz (0.7 nmol) were incubated with [64Cu]fCuCl2 (74–370 MBq) in 300 μL ammonium acetate buffer (200 mM, pH 5.5) at room temperature. - >99% radiochemical conversion |
Need this precursor?We can point you to suppliers for [64Cu]SarAr-PEG10-Tz, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41605863. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41605863: 'SarAr-Tz, SarAr-PEG5-Tz, and SarAr-PEG10-Tz (0.7 nmol) were incubated with [64Cu]fCuCl2'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Cu-64 agent whose theranostic partner cu67-sararpeg10tz carries the therapy isotope Cu-67: this is the imaging half of the pair. Linked articles: PMID 41605863. Stage set/updated at stage 39 from PMID 41605863: 'paired with a TCO-bearing variant of the A33 antigen-targeting antibody huA33 (i.e., huA33-TCO) for pretargeted immunoPET in a murine model of colorectal cancer'.